Intellia Therapeutics (NASDAQ:NTLA) stock is on the move Friday after releasing positive clinical trial data for two of its drugs.
NTLA-2002 is the first drug behind today’s NTLA stock movement. This is a gene-editing drug in development to treat hereditary angioedema ( ). It’s designed to “knock out” the KLKB1 gene in liver cells to reduce the production of the kallikrein protein.
The big news today is positive interim results from an ongoing Phase 1/2 clinical study of NTLA-2002. That includes significant reductions in plasma kallikrein and HAE attack rates.
More Clinical Trial Data Is Moving NTLA Stock
That’s not all, though. NTLA-2001 is the second drug that NTLA stock investors need to know about today. This gene-editing drug is in development to treat transthyretin (ATTR) amyloidosis. Yet again, positive Phase 1 interim data is top of mind.
The current clinical trial measures serum transthyretin (TTR) protein concentration after administering NTLA-2001. The company is noting a significant reduction in TTR when giving the drug to patients through intravenous infusion.
The clinical trial data has shares of NTLA stock seeing heavy trading today. As of this writing, more than 2 million shares have changed hands, well above the daily average trading volume of about 1.3 million shares.
NTLA stock started off up in pre-market trading today. However, shares are now down 7% as of Friday morning.
There’s more recent stock market news worth checking out below!
InvestorPlace has all the latest stock news traders need to know about for Friday! A few examples include why shares of General Electric (NYSE:GE) and NCR (NYSE:NCR) stock are on the move, as well as the latest real estate crash discussions. You can catch up on all of this news at the following links!
More Friday Stock Market News
- Why Is General Electric (GE) Stock Down Today?
- Why Is NCR Stock Down 23% Today?
- Real Estate 2022: The Ultimate Guide to the Coming Housing Market Crash
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.